- Home
- SLGN vs PCVX Comparison
SLGN vs PCVX Comparison
Compare SLGN & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLGN
- PCVX
- Stock Information
- Founded
- SLGN 1987
- PCVX 2013
- Country
- SLGN United States
- PCVX United States
- Employees
- SLGN N/A
- PCVX N/A
- Industry
- SLGN Containers/Packaging
- PCVX Biotechnology: Pharmaceutical Preparations
- Sector
- SLGN Industrials
- PCVX Health Care
- Exchange
- SLGN Nasdaq
- PCVX Nasdaq
- Market Cap
- SLGN 4.8B
- PCVX 4.0B
- IPO Year
- SLGN 1997
- PCVX 2020
- Fundamental
- Price
- SLGN $43.29
- PCVX $31.00
- Analyst Decision
- SLGN Strong Buy
- PCVX Strong Buy
- Analyst Count
- SLGN 9
- PCVX 8
- Target Price
- SLGN $62.22
- PCVX $114.17
- AVG Volume (30 Days)
- SLGN 972.0K
- PCVX 1.4M
- Earning Date
- SLGN 10-29-2025
- PCVX 11-04-2025
- Dividend Yield
- SLGN 1.85%
- PCVX N/A
- EPS Growth
- SLGN N/A
- PCVX N/A
- EPS
- SLGN 2.81
- PCVX N/A
- Revenue
- SLGN $6,162,113,000.00
- PCVX N/A
- Revenue This Year
- SLGN $11.89
- PCVX N/A
- Revenue Next Year
- SLGN $2.79
- PCVX N/A
- P/E Ratio
- SLGN $15.41
- PCVX N/A
- Revenue Growth
- SLGN 5.49
- PCVX N/A
- 52 Week Low
- SLGN $43.18
- PCVX $27.66
- 52 Week High
- SLGN $58.14
- PCVX $121.06
- Technical
- Relative Strength Index (RSI)
- SLGN 29.69
- PCVX 43.55
- Support Level
- SLGN $43.76
- PCVX $31.47
- Resistance Level
- SLGN $45.49
- PCVX $33.32
- Average True Range (ATR)
- SLGN 0.73
- PCVX 1.23
- MACD
- SLGN 0.00
- PCVX 0.12
- Stochastic Oscillator
- SLGN 2.55
- PCVX 29.74
About SLGN Silgan Holdings Inc.
Silgan Holdings manufactures about half of the metal food containers in North America. Its major customers include Campbell Soup, Nestle, and Del Monte. Silgan's other business segments include plastic dispensers and containers for personal and healthcare products and a closures business that manufactures metal and plastic lids and caps.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.